

BICO Group adds senior IR manager to its executive management

Åsa Hillsten has been appointed SVP and Head of IR at BICO and will be a member of the company's executive management. This newly created position constitutes a step in BICO's continued efforts to increase the service level to the market, improve the clarity of its communication and clarify its business model for the investor market.

Åsa Hillsten has more than fifteen years of solid experience in international strategic communication and IR issues at the executive management level at growth companies in several sectors. Former positions include Head of IR and communication roles at Catena Media (mid-cap) and Collector Bank (large cap), where she was also Head of PR.

"We are incredibly pleased to welcome Åsa Hillsten to BICO," says Erik Gatenholm, President & CEO of BICO. "Her recruitment to this newly created position is a step in the company's transfer to Nasdaq Stockholm's Large Cap list in 2022. BICO has a clear growth strategy and made several major acquisitions in 2021. These acquisitions have now been consolidated, and BICO is well equipped to deliver the best solutions available in the bio convergence market. BICO creates the necessary conditions for generating organs using cells from our own bodies. This puts us on our way to resolve the worldwide problems associated with the worldwide shortage of organs and donors. We are at an exciting stage and are now strengthening our expertise even further."

"I am looking very much forward to adding value on BICO's continued journey," says Åsa Hillsten, the newly appointed SVP & Head of IR at BICO. "I find my motivation in scalable business models and the opportunity to work for a group that so clearly contributes to the future of health. My duties will include elucidating the company's business, technology and future opportunities and managing the market's expectations. My role also includes developing and ensuring regulatory compliance and clarifying the results generated by BICO for doctors active in the bioscience sector, owners and capital markets."

Hillsten will assume her position on August 8, 2022, but she will assist the company in an advisory capacity starting in May.

For further information, please contact:

Erik Gatenholm, President & CEO, BICO Group AB
Phone: +46 73 267 0000
E-mail: eg@bico.com

Åsa Hillsten, SVP Investor Relations, BICO Group AB
Phone: +46 70 344 854 17
E-mail: ash@bico.com

This information was submitted for publication, through the agency of the contact persons set out above, on May 12, 2022, at 07:00 (CEST).

About BICO

Founded in 2016, BICO (formerly CELLINK) is enabling the future of life-saving treatments by reducing the organ shortage and accelerating drug development by providing accessible life science solutions that combine biology and technology (bioconvergence). The company focuses on developing, manufacturing, selling, and supporting its life sciences equipment, consumables, and reagents for both manufacturing as well as research purposes. BICO has more than 25,000 products in the field, sales in more than 65 countries, delivers to all top 20 pharmaceutical companies, and have been cited in more than 10,000 scientific publications. BICO is listed on Nasdaq Stockholm under: BICO.